ArticleScientific reports2025
Identification of autoantibodies against HIF1a in patients with anorexia nervosa and their potential role in hepatic cytolysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anorexia nervosa (AN) is a severe, potentially life-threatening psychiatric disorder characterized by an intense fear of weight gain, a distorted body perception and an extern food restriction leading to an abnormally low body weight. In AN patients, malnutrition is often associated with hepatic cytolysis. A growing body of evidence support an association between AN and auto-immunity. In this exploratory study, we revealed for the first-time the presence of autoantibodies targeting hypoxia-inducible factor 1 alpha (HIF1a) in AN. We evidenced the presence of autoantibodies against HIF1a in 22% of AN patients, which were absent in patients with other metabolic disease as type-I diabetes or in healthy subjects. In addition, we found that HIF1a autoantibodies was associated with hepatic cytolysis in 80% of AN patients and that their levels significantly correlated with those of ALT (alanine aminotransferase). In-vitro experiments demonstrated that HIF1a autoantibodies induced hepatocyte lysis, suggesting a potential link between these autoantibodies and liver dysfunction in AN patients. Altogether, our data reveal an implication of HIF1a autoantibodies in AN with hepatic cytolysis. Future investigation will explore their potential as a diagnostic or a prognostic marker in AN, but also other diseases since dysregulated hypoxia pathway has been implicated in other pathologic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.